Ivosidenib – Another feather in the hat of treatment for acute myeloid leukemia
The treatment of acute myeloid leukemia has undergone a paradigm shift in the past few years. Multiple new targeted and nontargeted agents have been approved in the recent past. Isocitrate dehydrogenase (IDH) mutation is one such target that has been identified, and two new drugs, ivosidenib and ena...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2020-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=4;spage=552;epage=554;aulast=Perumal |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The treatment of acute myeloid leukemia has undergone a paradigm shift in the past few years. Multiple new targeted and nontargeted agents have been approved in the recent past. Isocitrate dehydrogenase (IDH) mutation is one such target that has been identified, and two new drugs, ivosidenib and enasidenib have been approved. The former is an IDH1 inhibitor, and the latter is an IDH2 inhibitor. The mechanism of action, key trials, adverse events, and monitoring of ivosidenib has been discussed in this article. |
|---|---|
| ISSN: | 0971-5851 0975-2129 |